Emerging in the field of obesity treatment, retatrutide represents a distinct strategy. Beyond many current medications, retatrutide functions as a twin agonist, concurrently affecting both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic hormone (GIP) sensors. The simultaneous stimulation promotes several helpful effects, such as better